Results 181 to 190 of about 203,196 (295)
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu +3 more
wiley +1 more source
Correction to: Surgical management of giant splenomegaly in chronic myeloid leukemia: a challenging splenectomy case. [PDF]
europepmc +1 more source
Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties. [PDF]
Mayer J.
europepmc +1 more source
Prospective functional MRI brain and neurocognitive assessments were performed serially during intensive chemotherapy for a cohort of adults with newly diagnosed acute myeloid leukaemia to elucidate ‘chemobrain’ language phenomena. At completion of consolidation, significant reductions in functional and microstructural connectivity were observed ...
Ashleigh P. Scott +17 more
wiley +1 more source
Restless legs syndrome in chronic myeloid leukemia: an overlooked condition with a significant impact on health-related quality of life. [PDF]
Gürer T +11 more
europepmc +1 more source
Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies [PDF]
Allegra A. Petti +21 more
core +2 more sources
HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia. [PDF]
Toulemonde C +15 more
europepmc +1 more source
Summary Genomic technologies including next‐generation sequencing (NGS) and arrays for cytogenetic anomalies are now standard of care in England for the diagnostic evaluation of patients with suspected haematological malignancies. Challenges remain in the management of potential germline findings as a result of NGS panels and copy number variant ...
B. Speight +12 more
wiley +1 more source

